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Abstract. In clinical trials which target pathophysiological mechanisms associated with Alzheimer’s disease, research par-
ticipants who are recruited based on biomarker test results should be informed about their increased risk of developing
Alzheimer’s dementia. This paper presents the results of a qualitative focus group study of attitudes and concerns toward
learning information about biomarker-based risk status among healthy research participants in the United Kingdom and
Spain and people with dementia and their supporters/caregivers from countries represented in the European Working Group
of People with Dementia of Alzheimer Europe. The study identified expectations related to learning risk status and prefer-
ences related to the content, quality, and follow-up of the disclosure process. The latter emphasize distinctions between risk
and diagnoses, the importance of clear information about risk, and suggestions for risk reduction, as well as expectations
for follow up and support. The implications of these preferences for practice are discussed. Providing details of research
participants’ experience and views may serve as a guide for the development of processes for the responsible disclosure of
Alzheimer’s disease biomarkers.
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INTRODUCTION
Research in Alzheimer’s disease increasingly
focuses on identifying risk statuses indicated by bio-
logical markers of pathological changes associated
with later dementia, notably levels of amyloid- in
cerebrospinal fluid or on PET brain imaging. How-
ever, although significant research is ongoing, the
clinical validity and value of biomarker informa-
tion for asymptomatic individuals is still open to
question [1]. The communication of biomarker infor-
mation to people without symptoms of dementia thus
presents an ethical challenge for researchers and,
should such approaches translate into clinical prac-
tice, for clinicians [2, 3]. Routine communication
of risk information to people without symptoms in
clinical practice is currently not recommended [4, 5]
considering the lack of robust individualized predic-
tion [6] and the potential psychosocial harms caused
by learning one’s risk status in the absence of effec-
tive preventive or therapeutic options [7]. Attention
has also been drawn to the potential of broader test-
ing and screening programs associated with earlier
stages of Alzheimer’s disease to result in premature
diagnoses and over-treatment of age-related cognitive
change [8].
Nevertheless, in research settings there are two
reasons why it may be acceptable or appropriate
to communicate biomarker information related to
Alzheimer’s dementia risk to people without symp-
toms [9]. Some participants will want to know their
estimated risk status, and communicating these indi-
vidual research results may be an expression of
respect for their autonomy and a form of reciprocity
in some circumstances [10, 11], even if this informa-
tion is not currently actionable and the exact meaning
of risk prediction and specific biomarkers within risk
prediction in an individual is unknown. It has been
estimated that between 50% and 90% of people are
interested in knowing the results of a ‘predictive’
or ‘reliable’ test of their risk of developing demen-
tia, with numbers varying across countries [12–17].
However, when people’s understanding of the current
uncertainty and limited generalizability and clinical
validity associated with biomarkers increases, their
interest in learning about the biomarker wanes [15].
In fields where tests are predictive rather than prob-
abilistic, experience suggests that actual uptake may
be lower than anticipated, particularly in the absence
of treatment [18]. It is thus likely that levels of pub-
lic interest in learning Alzheimer’s disease risk are
overestimated.
A more compelling reason for disclosure relates
to recruitment for clinical trials. Clinical trials are
currently ongoing which target pathology in a popula-
tion of relatively younger, asymptomatic individuals
identified as being at ‘high risk’ of developing
Alzheimer’s dementia on the basis of family histo-
ries, genetic information, and biomarker tests [19,
20]. Within these studies, prospective research par-
ticipants should know why they have been invited to
take part in a study in order to make informed deci-
sions about research participation [21] as part of a
transparent recruitment process [22].
There is a small but growing body of evidence
related to the impact of disclosure which suggests
that learning that one is at elevated risk of developing
Alzheimer’s dementia in the absence of symptoms
of dementia does not cause significant psychological
or social harm [23]. However, although the imme-
diate psychological impact of risk disclosure seems
limited, there is an increase in test-related distress,
and adverse psychological effects occur in a sub-
group of research participants. Results from the Risk
Evaluation and Education for Alzheimer’s Disease
(REVEAL) studies suggest risk disclosure may have
implications in relation to long-term care insurance
and possibly to health-related behavior changes [24].
Although not directly comparable, there is also evi-
dence that diagnoses of mild cognitive impairment
and mild Alzheimer’s disease dementia are associ-
ated with lower quality of life [25]. Recent studies
suggest a low risk of psychological harms associated
with disclosure of Alzheimer’s disease biomarkers
[26, 27].
However, the evidence remains limited: there has
been little analysis of the impact of risk disclosure
in relation to non-genetic biomarkers and there is
sparse evidence on disclosure outside the United
States despite geographical variation in interest in
knowing [16] and important differences across coun-
tries in long-term care provision. Published work on
ApoE genetic testing concentrates on individuals who
are first-degree relatives of a person with Alzheimer’s
dementia [28], who may already perceive themselves
to be at increased risk due to this history [29]. Fur-
ther, there is potentially important variation in the
experience of family history, notably between cases
in which dementia occurs late in life and close to death
rather than earlier in life [30, 31]. In sum, the impacts
of biomarker disclosure on healthy research partici-
pants remain to be studied. Importantly, the impact
of disclosure is also likely to be affected by the man-
ner in which information about amyloid biomarkers
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is presented to the research participant. Careful atten-
tion is needed to determine whether people want to
learn information about biomarkers for Alzheimer’s
dementia, what this information should include, and
when and how it should be communicated [32].
There are no current shared guidelines for com-
municating amyloid biomarkers, and a small number
of descriptions of current practice have been pub-
lished to date. The most detailed of these are those
elaborated in clinical research settings for the com-
munication of amyloid PET imaging to asymptomatic
individuals [27, 33] and to those with mild cognitive
impairment [34]. Clinical communication models
focus on shared decision-making with regard to amy-
loid testing and standardized language to describe the
clinical significance of amyloid biomarkers [35–37].
The disclosure process described by Harkins
et al. [33] is the most clearly elaborated and
detailed approach within a research setting pub-
lished in the literature to date. It was developed
for initial use in the Anti-Amyloid Treatment in
Asymptomatic Alzheimer’s Disease (A4) study [20]
(NCT02008357), which recruits participants based
on positive results on amyloid PET imaging. It draws
on a Delphi consultation with experts in genetic test-
ing and neuroimaging.
The A4 disclosure process starts with education
in the form of an information brochure provided in
advance of the initial consent visit. This sets out the
state of knowledge about amyloid imaging, the range
of possible results, and their implications. The infor-
mation in the brochure is then discussed in detail
during the consent process, along with the moti-
vations of potential participants to join the study.
Comprehension of the brochure is then assessed, and
potential participants are screened for anxiety and
depression to establish their suitability to receive
amyloid biomarker results. The actual PET imaging
takes place at a second visit, and disclosure at a third
visit. Prior to the disclosure of results, study staff
again ascertain a participant’s willingness to learn the
results, their mood, and whether they have had recent
life stress. Harkins et al. emphasize the importance
here of involving staff who are skilled in communicat-
ing and recognizing distress. Disclosure itself occurs
using standardized language which reflects that used
in the information brochure and is accompanied
by written information and with a family member
or friend present if desired. Comprehension of the
results is then assessed. Participants are followed up
by phone three days after disclosure to assess well-
being, distress, and the impact of disclosure, with a
follow-up plan created based on responses. Finally,
participants are followed up over the course of the
study. The approach described by Burns and col-
leagues [27] for the Alzheimer’s Prevention Through
Exercise (APEX) study (NCT02000583) is similar.
Notable characteristics are an emphasis on the prob-
abilistic nature of both ‘elevated’ and ‘nonelevated’
amyloid results, a policy not to share scan results
with the participant’s physicians or enter them into
the medical record, and follow-up by phone or e-mail
at six weeks and six months.
The approach developed by Lingler et al. [34]
focuses on the disclosure of amyloid status to peo-
ple with mild cognitive impairment. Their guidance
starts from guidance on genetic counselling and an
iterative expert consultation, and was then tested
and refined with mild cognitive impairment patients
and caregivers. This approach also emphasizes the
importance of pre-disclosure counselling and post-
disclosure assessments of comprehension and the
value of involving family or friends in the disclo-
sure process. It also contributes important points on
the content of information—highlighting the possi-
ble value of using brain images and the importance
of clear graphics, as also increasingly recognized
in the communication of genetic risk [38]. Finally,
participants in the study by Lingler and colleagues
expressed a desire for seamless communication with
primary care providers.
The research reported in this paper was conducted
to inform the development of the risk disclosure pro-
cess during recruitment to trials within the European
Prevention of Alzheimer’s Dementia (EPAD) project
[39, 40], a longitudinal cohort study and clinical trial
platform for the secondary prevention of Alzheimer’s
dementia. The paper examines the perspectives of
individuals with no symptoms of dementia, people
with dementia, and caregivers on the communication
of Alzheimer’s dementia risk. No biomarker informa-
tion has been communicated to these individuals, and
the paper briefly describes their expectations related
to the implications of learning information related to
Alzheimer’s disease risk status. The paper then sets
out the preferences of participants related to the con-
tent, process, and follow-up of biomarker-based risk
disclosure in research settings. These preferences are
intended not to be prescriptive, but to reflect qualities
of Alzheimer’s disease risk communication consid-
ered important by those who may be involved in
it in the future, and which should be engaged with
by researchers and clinicians in the development of
disclosure processes.
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METHODS
Focus groups were held in London and Barcelona
between November 2015 and January 2016, and in
Brussels in December 2015. Spanish participants
were recruited through the BarcelonaBeta Brain
Research Centre (BBRC) of the Pasqual Maragall
Foundation [41]. Participants in the United Kingdom
were recruited through the Prevent cohort study [42].
The group discussion held in Brussels was comprised
of participants recruited from within Alzheimer
Europe’s European Working Group of People with
Dementia1 (EWGPWD). The aim of this latter group
was to obtain the perspective of people with demen-
tia. This allowed the investigators to explore further
the relationship between the diagnostic and risk dis-
closure processes. The study was approved by ethics
committees in both Cambridge (NHS REC Reference
15/EE/0381 and University) and Barcelona.
Four groups were held in both London and
Barcelona, three with people with a first-degree rel-
ative with Alzheimer’s dementia, one with people
without this family history. In total, 48 people par-
ticipated, 32 in Spain and 16 in the UK. Group
sizes ranged from 3 to 10. The participants included
30 women and 18 men, all of whom identified as
Caucasian. 34 of the participants (71%) had a fam-
ily history of dementia. Further details are given in
Table 1. The EWGPWD group included 6 people
with dementia (4 women, 2 men, median age 64.5)
and 4 partner caregivers (2 men, 2 women, median
age 66.5). Demographic data other than age were not
collected from this group.
The individuals recruited for the focus groups in
London and Barcelona were purposively sampled
to be indicative of the likely future population for
Alzheimer’s disease clinical trials involving risk dis-
closure. They are research-engaged individuals, who
are more likely to have a family history of demen-
tia. While their views may not be representative of
the population, they have immediate relevance to
questions regarding the development of responsible
disclosure processes in research. The participants
1 In 2012, Alzheimer Europe set up a Working Group of People
with Dementia (EWGPWD). The EWGPWD is composed of 10
people with dementia from different countries and with different
types of dementia. The EWGPWD works to ensure that the activ-
ities, projects and meetings of Alzheimer Europe duly reflect the
priorities and views of people with dementia. The group operates
independently, with its own Board and agenda of activities. The





Number of participants 16 32
Female 10 20
Male 6 12
Family history of AD dementia 12 22
Median age 55 (43–59) 61 (48–76)
Median years education 17 (13–22) 15 (8–18)
from the EWGPWD, as members of a pre-existing,
established group, represent a convenience sample.
The groups were conducted according to the same
protocol at the sites in London and Barcelona (see
Supplementary Table 1). An adapted protocol was
used for the EWGPWD. Participants were provided
with short background information on biomarker-
oriented research into Alzheimer’s disease. The
structured protocol then asked a series of questions
related to 1) this background information; 2) partic-
ipants’ interest in learning their Alzheimer’s disease
risk, and the implications of this information, 3)
how this differed for different types of risk informa-
tion, and 4) preferences related to disclosure. This
paper reports focuses on findings related to sections
2 and 4.
The focus groups were recorded and transcribed
verbatim. Groups in London and the EWGPWD
were conducted in English, while the Barcelona
groups were conducted in Spanish and translated into
English as part of the process of analysis. A coding
framework was developed and used by RM and AD
to identify key themes in the transcripts at each site.
Data coded to these themes was then shared and used
in further iterations of coding and analysis. Following
an initial discussion of the themes emerging from the
data at each site which identified comparable results,
data from both sites was analyzed together.
The investigators identified preferences related to
disclosure from initial analysis of the discussions in
section 4 of the protocol related to the process of dis-
closing Alzheimer’s disease risk information. These
were collated by RM and AD and written up for par-
ticipants. This report was circulated by email to the
participants in Spain and the United Kingdom for
comment and respondent validation [43]. The partic-
ipants from the EWGPWD reviewed and agreed upon
the report in a face-to-face meeting.
The study has a number of limitations. First,
the findings relate to expectations of the disclosure
process, rather than reflections on experiences of
disclosure. As such it involves some elements of
conjecture on the part of participants. Focus groups
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are particularly well suited for these types of ques-
tions, as the focus on interaction enables people
to draw on both their own experience and that
of others as discussions develop. However, focus
group methods also have limitations, not least the
limited generalizability of the results and the diffi-
culty and limited value of quantifying perspectives
which emerge during group interaction. In the current
work, it was also necessary to develop the protocol,
facilitate the groups, and analyze the data while work-
ing across languages and cultures. This required a
more structured approach to facilitation and protocol
design to enable the production of comparable data
than might have been adopted in a single-language
setting, and further detailed work is needed to explore
cultural differences related to disclosure and atti-
tudes to dementia risk. Nevertheless, the current work
provides a set of preferences related to disclosure
generated and reviewed by participants which rep-
resent a starting point for consideration and further
exploration.
RESULTS
The first section presents the results of the group
discussions related to why participants would be
interested in or willing to learn their Alzheimer’s
disease risk status, and what they saw as the poten-
tial limitations and concerns associated with doing
so. Results from the EWGPWD group discussion are
based on slightly reformulated questions as the par-
ticipants already have dementia. Consequently, in this
section, the views expressed by this group should be
interpreted not on the basis of how they are affected
but rather on how they would have been affected in
the past.
Section two presents the preferences related to dis-
closure processes in research settings.
The potential benefits of knowing
Participants were interested in learning their risk of
developing Alzheimer’s dementia, primarily because
of the perceived personal utility of the information:
“Information is good, it puts the problem on the
table, if you do not have more risk, great, and if
you do then you can remedy it.” (SP1)
The most prominent discussion was whether the
information was valuable for acting to reduce risk.
However, the link between knowledge and action
was seen as problematic given the uncertain predic-
tive value of risk information and the lack of proven
options for risk reduction:
“[I]f the probability was uncertain, I would also
want to know it, but surely I would be less inter-
ested, because I do not know if I can use this much
to make decisions.” (SP2)
“[I]f you told me that I was at a high risk I would
certainly want to have, um, advice. How do I go
on from here, what can I do to prevent it from
getting any worse, or developing into a full-scale
thing?” (EWGPWD supporter/caregiver)
Information about risk status is thus seen as valu-
able when it has personal utility. Where this is absent,
the perceived benefits are diminished.
The potential harms of knowing
The provision of information in the absence of
available courses of action raises concerns about the
short and longer-term impact of knowing for indi-
viduals and their families. As the participant quoted
above continued:
“Otherwise I don’t think I would like you to tell
me, because what could I do? And why should
I carry this worry, and why should I burden my
family with this kind of worry?” (EWGPWD sup-
porter/caregiver)
Focus group discussions introduced two forms
of impact which might be considered harmful:
short-term psychological effects and longer-term
hypervigilance.
Short-term effects
Participants rarely described expecting effects on
their mood or anxiety following risk disclosure. This
absence is important for understanding how people
comprehend risk information, and reflected the role
of family history in shaping risk perceptions:
“Even if I didn’t do any of this [testing] I feel
my risk is high. Therefore, would it affect me if
somebody actually quantified it?” (UK1)
However, when risk information was seen to be
highly predictive and the development of dementia
imminent a small group of participants suggested that
they would consider using this information to inform
suicide or assisted suicide to avoid the suffering they
expected to result from Alzheimer’s dementia:
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“I want to know immediately, that is, even a risk
of 80%, not 99%, to make my own decisions,
because I will not go through what happened to
my father, I am very clear. Bump me off before I
get to be like [that].” (SP2)
This expectation was based upon personal expe-
riences with the disease (e.g., in one or more
first-degree relatives). Equally commonly however,
participants referred this reaction to others, suggest-
ing that although they would find the information
useful, as discussed above, other people who were
told they were at risk might mis- or over-interpret its
significance.
Longer-term effects
Participants’ main discussions of the effects
they expected to be associated with learning their
biomarker status relate to the longer-term. Partici-
pants focused on how risk information could change
their perception of their own cognition, leading to
hypervigilance with regard to possibly dementia-
related symptoms:
“it could be that if you’ve been assessed as having
a higher risk and then you’ve gone a couple of
days, and twice you’ve come down without the
thing you went up for . . . That could then make
you think, ah, this is the beginning of it.” (UK2)
This was seen by some as a drawback of learning
about one’s Alzheimer’s disease risk status. More-
over, this group further suggested that the revelation
of dementia risk could affect their relationships with
their families, including leading to their decisions
or views being “second-guessed” (UK2). This ongo-
ing consideration might make people reconsider their
long-term plans:
“I think it’s the practical side of it that would
worry me, I guess. Would it make me think dif-
ferently about where I lived and how I moved”
(UK1)
While this was worrying for some participants,
it was also seen as potentially valuable in terms of
accessing earlier assistance from health and social
services. This assessment contributed to participants’
preferences related to the disclosure process and
follow-up.
Preferences related to the disclosure process
The considerations of value, limitations and impact
were used to outline a series of preferences related to
the risk disclosure process in research. These cover
the process of communicating Alzheimer’s disease
risk information, from the framing and the content of
the information, to the conduct of disclosure, and the
follow-up.
1. The communication process should make it
clear that it relates to a risk rather than a
diagnosis.
“It should also be emphasized that it is not a diag-
nosis, it is a suggestion that you are at high risk.
So therefore you could calm the situation down a
bit.” (EWGPWD, participant with dementia)
The first preference expressed by participants was
that the communication of biomarker test results
should highlight the appropriate framing of risk infor-
mation and distinguish it from the communication of
a diagnosis.
2. Information should provide clear details on risk
level.
“A diagnosis is certain, but what about risk? If
they tell me that I have a 10% or 80% possibility
it is not the same. If it is 80% or more then I want
to know, but if not, why [would I]? And the when
also, whether it is tomorrow that I could develop
it, in 2 or 3 years and within 20, because if it is in
20 years I will have already died and what would
all the stress be for, for all this. For me the key
is in the information, in the type of information.”
(SP1)
Participants recommended that information should
detail and quantify the level of risk described
wherever possible. As this quote illustrates, this infor-
mation would give detail beyond a simple increase in
risk, but an idea of the time to which it refers.
3. Information should be accompanied with sug-
gestions for action.
“If they tell you, or if you want to know, they have
to put the cards on the table and say, ‘You are in
this situation, but you have this, this and this you
can do.”’ (SP3)
This expectation that risk information would be
accompanied by information about risk reduction
reflects the central reason that our respondents were
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interested in knowing their Alzheimer’s disease risk
status, that it might enable them to act to reduce this
risk.
4. Information should be provided by experts with
the necessary knowledge and skills.
“P1: Well that was my concern, is somebody
telling me information very casually, and I would
want somebody that’s really interested and has
the time . . .
P2: And an encyclopedic knowledge of this.”
(UK1)
Participants emphasized that individuals with an
appropriate level of expertise and an ability to com-
municate sympathetically should be responsible for
communicating information related to risk.
The precise identity or professional role of the
individual responsible for communicating risk infor-
mation was not specified by group participants, and
indeed may vary between settings. Some referred to
a combination of “medical and social experts who
might give advice as to what one might and might
not do” (SP3).
5. Information should be provided face-to-face.
“Face to face, definitely. I mean not if, if the
answer’s, ‘No, you’re just at an average risk,’
then fine, you know. An email or a letter would
be fine. But if the answer is that you’re identified
as being at high risk then I think that should be a
face to face conversation.” (UK4)
The preference among participants in this research
was for disclosure of risk status to occur in a face-
to-face meeting. This conclusion was supported by
examples of experiences with brusque or inappropri-
ate disclosure of diagnoses or clinical information
in the past. While this discussion may evolve as
Alzheimer’s disease risk information becomes more
commonplace, it suggests that research participants
prefer that disclosure in research settings starts from
face-to-face encounters.
6. Time should be allowed for questions before,
during and after disclosure.
“I think if you’re going to, you know, if you’re
going to tell people about this kind of stuff they’ll
be like, OK, fine, but what does it mean to me,
and where can I go with this information? So you
can give me lots of information but can I have a
conversationwith somebody one-to-one about the
implications of that for me personally?” (UK2)
Participants expected that time would be made for
discussion of the likely meaning of test results before
receiving them and for interpretation of the results
themselves. Also, they suggested that they would
expect research teams to be available after disclosure
for further and follow-up questions.
7. Communication should occur consistently
across settings.
“I’m cautious of the role of my GP, the GP. So I
would like to have some information [on] what I
can tell him, or a piece of paper, so that he can
get it in his own vocabulary, not through me as
an amateur.” (EWGPWD, caregiver/supporter)
The preference for expert-led disclosure has impli-
cations for the portability of risk information, i.e.,
the use and interpretation of test results outside the
research study. A concern raised by participants was
that, as Alzheimer’s disease risk markers are not
routinely used in healthcare, non-expert clinicians
including primary care physicians might provide
alternative interpretations.
8. People at increased risk should be monitored
following disclosure.
“I don’t know what’s out there but, um, that sense
of responsibility lying on the patient’s or the indi-
vidual’s head is quite onerous sometimes, and so
if there were, right OK once every two years or
once every year or whatever have a check-up,
like you’re in a system where you’re held and
contained and monitored, that would be good”
(UK4)
Participants suggested that people who are told
they are at higher risk of developing Alzheimer’s
dementia would anticipate a regular check-up with a
doctor, or at least some monitoring of their cognitive
status.
9. Psychosocial support should be available.
“I think if there is a test you give people the oppor-
tunity to know one way or the other, and then,
the only thing is then if they decide to take that
information is you have to provide them with the
knowledge that they’re susceptible, and you then
have to have the support network.” (UK3)
Finally, participants described the availability of
longer-term psychological and emotional support,
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not necessarily provided by clinicians or the research
team. Discussions emphasized the potential value of
establishing forums for broader support and discus-
sion extending over a longer period.
DISCUSSION
Focus group participants’ discussions of the likely
benefits and harms associated with learning informa-
tion related to Alzheimer’s disease risk emphasize
the perceived personal utility of the information.
These findings correspond with those raised in similar
research on both the hypothetical and actual impact
of learning the results of biomarker tests related to
Alzheimer’s disease risk [14, 15, 17, 44]. In line with
the findings of REVEAL and similar studies, they
suggest the short-term psychological impact of risk
information may not generally result in harm, but that
there may be subgroups who experience significant
negative impacts.
The discussions reported here do, however, draw
attention to the longer-term impacts of risk informa-
tion, not least the potential for hypervigilance and
long-term monitoring among people who already
feel they are at risk of developing dementia. Risk
information should thus be considered in terms of
its potential contribution to ‘dementia worry’ [45,
46] and the danger of introducing a diagnostic mis-
conception, whereby people who undergo research
diagnostic procedures come to see themselves and
are seen by others as patients although they would
not have received any diagnosis in a standard clini-
cal setting [47]. This is important in considering the
implications and assumptions involved in the prefer-
ences of research participants related to the disclosure
process.
Preferences concentrate on the content of the
information, the quality of communication, and the
follow-up process. Discussions of content empha-
size the importance of attending to the language used
in discussions of biomarker test results, and distin-
guishing between risks and diagnoses. This reflects
the potential difficulties which have been highlighted
elsewhere [48] associated with using terms such as
‘preclinical Alzheimer’s disease’ to refer to individ-
uals who have no symptoms of dementia. In practice,
it can be difficult for investigators to effectively
communicate this distinction, and risk statuses do fre-
quently become elided with diagnoses by both people
at risk and clinicians [49]. For example, in stud-
ies involving the disclosure of mock PET results to
people with mild cognitive impairment and care part-
ners, even when researchers clearly stated that PET
evidence of amyloid was not synonymous with a
clinical diagnosis of Alzheimer’s disease, this rela-
tionship was still presumed by recipients [50].
Attention is thus needed to effective communi-
cation of both risk and ambiguity. Guidance on
risk communication is well developed in relation
to genetic testing, where data on relative and abso-
lute risks are more readily available. Research
groups have effectively used pictographs and other
visual presentations of risk (e.g., video) to help
research participants understand relative and absolute
risks conveyed by genetic susceptibility markers for
dementia [38, 51]. However, the lack of precise infor-
mation about the risk associated with non-genetic
biomarkers of Alzheimer’s disease (notably related
to amyloid load), and the timescale to which the risk
refers, makes such an approach difficult to imple-
ment. Research is ongoing to improve the accuracy
of biomarker testing [39, 41, 42]. However, cur-
rently, this limitation should be addressed through
the development within these studies of informa-
tion or education materials to accompany disclosure
processes [33, 40]. In line with the findings from qual-
itative work following amyloid disclosure, these may
need to address how classifications of amyloid ‘posi-
tive’ or ‘negative’ are produced [32], and should also
be transparent about the scientific uncertainties asso-
ciated with biomarkers [52]. However, more work is
also needed to inform the communication of scien-
tificambiguityor epistemic uncertainty [53] related to
Alzheimer’s disease, as well as in our understanding
of the concept of Alzheimer’s disease itself, given that
the majority of individuals die with these pathologies
in their brains and that, among the oldest old—the age
of greatest risk for dementia—the risk of Alzheimer’s
dementia associated with these pathologies is
attenuated [54, 55].
This emphasis on uncertainty is important in con-
sidering discussions related to providing information
on risk reduction. In practice, it appears rare for
research participants to use genetic risk informa-
tion, including that related to Alzheimer’s disease,
to change their behaviors to reduce health risks [56].
Nevertheless, some individuals identified as being
at higher risk will wish to act upon it [57]. Pro-
viding well-evidenced information on risk reduction
as part of the disclosure process would recognize
this perceived value and may also reduce the harms
associated with learning about disease risks without
having any actionable options available. However,
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while there is consistent evidence of beneficial asso-
ciations between mid-life physical activity and other
exposures, healthy aging, and disease outcomes [58],
the available evidence about prevention does not yet
clearly point to the efficacy of particular activities or
behaviors in preventing the onset of dementia [59].
As in the discussion of risk information, communi-
cation related to risk reduction should highlight the
current state of the evidence and persistent uncer-
tainties, and be updated as further evidence becomes
available [60].
Concerns related to expertise and the consistent
interpretation of results echo those of participants
in relation to amyloid disclosure in mild cogni-
tive impairment [34]. They suggest an education
and liaison role for Alzheimer’s disease researchers,
healthcare professionals, and Alzheimer’s associ-
ations to ensure that the existence of research
diagnostic classifications for Alzheimer’s disease
[61] and associated technologies is recognized. The
focus on education, follow-up, and in-person dis-
closure highlights the potential benefits of learning
from the genetic counselling model, in line with the
approach proposed by Harkins and colleagues [4].
In particular, such models highlight the importance
of shared decision making and two-way communica-
tion [36, 62]. However, it is also important to remain
cognizant of material differences between ‘state’ and
genetic ‘trait’ information [28], notably the poten-
tial for levels of amyloid change over time, and the
unclear nature of the relationship between amyloid
load and the development of dementia. Importantly,
this involves re-emphasizing the limits in the evi-
dence base of biomarker-based Alzheimer’s disease
risk information in order to reduce the potential for
over-treatment and the reification of a diagnostic mis-
conception [63].
The preferences described here highlight the
importance of considering the nature and extent of
short and longer-term follow-up after the communi-
cation of biomarker status. Involving wider health
professionals, particularly primary care clinicians,
would enable participant preferences in relation to
monitoring to be met, possibly providing reassur-
ance in the context of hypervigilance. However, such
monitoring could also intensify the impact of risk
information, complicate its relationship with a clin-
ical diagnosis and possibly impact on life insurance
and employment status. Regular check-ups with med-
ical specialists would start to blur the clear boundaries
between ‘research’ and ‘clinical’ criteria proposed in
the 2011 NIA-AA definitions. In such circumstances,
it remains to be established that the potential harms
associated with unnecessarily treating individuals
who may never develop dementia outweigh the ben-
efits to those who would. It would also have resource
implications for healthcare systems, although the
costs of monitoring, surveillance, and preventive
treatment of asymptomatic individuals with increased
risks of Alzheimer’s dementia are difficult to esti-
mate accurately [64]. As current research studies
will not routinely refer at-risk participants to medi-
cal care, it is not expected that major financial effects
on healthcare systems will occur imminently. How-
ever, research groups should be prepared to discuss
and address expectations related to support and future
care, rather than automatically introducing such mon-
itoring with unknown consequences for participants,
health systems costs, and harms through diversion of
resources.
Risk communication should be a two-way pro-
cess, supported through a clear procedure for
dialogue, encouraging and responding to follow-
up questions and identifying individual needs and
concerns. Recommendations on disclosure empha-
size the importance of short-term follow-up by the
research team, for instance through a telephone call
a few days post-disclosure [33, 34]. A member of
the research team should be easily accessible for
research participants post-disclosure, for instance by
telephone. However, participants in this research also
highlight the value of longer term follow-up, in line
with the six week and six month contact described
in the APEX study [27], and of broader support net-
works of family and friends [33, 34]. Again, though,
this requires a careful approach which avoids reify-
ing a risk status as a diagnosis, and emphasizes that
people who learn they are at higher risk do not have
any cognitive impairments, and are not and may never
become Alzheimer’s dementia patients.
CONCLUSIONS
Interest in learning risk information regarding
Alzheimer’s dementia seems common. Often, how-
ever, it is dependent on favorable estimations of the
predictive value and personal utility of Alzheimer’s
disease biomarkers: interest is lower when people
learn that biomarkers are not conclusive or informa-
tive and options to reduce risk of disease are limited or
absent. Respondents’ discussions dwelt more on the
long-term implications of risk information and the
production of hypervigilance than short-term effects.
496 R. Milne et al. / Perspectives on Communicating Biomarkers
Participants’ preferences related to the process
of learning risk information underline the need
for careful, responsible risk disclosure processes
in research settings. They have immediate impli-
cations for practice for researchers, clinicians, and
Alzheimer’s associations. Importantly, they highlight
the fine line and inherent ambivalence in trying to
offer an appropriate level of care and support and
to avoid an over-interpretation of the clinical signifi-
cance of biomarker-based risk information. Research
groups should be careful to prevent the care and
support they offer from reinforcing the diagnostic
misconception and resulting in the harms and burdens
associated with hypervigilance.
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